IMPACT OF TREATMENT OF DIABETIC MACULAR EDEMA ON VISUAL IMPAIRMENT IN PEOPLE WITH TYPE 2 DIABETES MELLITUS: A COMPREHENSIVE SYSTEMATIC REVIEW AND METAAANALYSIST STUDY
DOI:
https://doi.org/10.61841/ja4d6761Keywords:
Diabetes mellitus, diabetic macular edema, diabetic retinopathy, vision impairmentAbstract
Background: Diabetic retinopathy (DR) and diabetic macular edema (DME) are among the most significant and disabling chronic complications of diabetes mellitus. DME is an important cause of severe vision loss in type 2 diabetes. Hyperpermeability of retinal blood vessels and subsequent formation of edema and hard exudates are the key clinical features.
Method: This systematic review and meta-analysis, conducted following PRISMA guidelines and employing the PICO format, aim to explore about impact of treatment of diabetic macular edema on visual impairment in people with type 2 diabetes mellitus, focusing on treatment, complications, and prognosis. Inclusion criteria encompass diverse study designs (RCTs, observational, quasi-experimental, and case-control studies) investigating impact of treatment of diabetic macular edema on visual impairment in people with type 2 diabetes mellitus among treatment, complications, and prognosis, while exclusion criteria filter out studies lacking relevance to impact of treatment of diabetic macular edema on visual impairment in people with type 2 diabetes mellitus.
Result: After conducting three levels of screening, the results of our search in Pubmed get 6 articles, whereas the results of our search on SageJournal get 42 articles, on Lancet 21, and on Scient direct get 60 articles. Records remove before screening are 91, so we get 78 articles for screening. After we screened based on record exclude, we compiled a total of 10 papers. We included four research that met the criteria.
Conclusion: There is a particularly robust response to anti-VEGF therapy in both groups when glycemic control is optimized, highlighting the critical importance of communication between the physicians managing the DME and those managing systemic diabetes control. Improving our understanding of the factors that contribute to anti-VEGF response for DME therapy may help to enhance DME treatment outcomes, particularly through the concerted coordinated efforts of the treating retina specialist and the endocrinologist or primary care physician.
References
Kitano S, Sakamoto T, Goto R, Fukushima A, Vataire AL, Hikichi Y. The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan. J Med Econ [Internet]. 2019;22(3):254–65. Available from: https://doi.org/10.1080/13696998.2018.1558867
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis [Internet]. 2015;2(1):1–25. Available from: http://dx.doi.org/10.1186/s40662-015-0026-2
Matsuda S, Tam T, Singh RP, Kaiser PK, Petkovsek D, Zanella MT, et al. Impact of Insulin Treatment in Diabetic Macular Edema Therapy in Type 2 Diabetes. Can J Diabetes [Internet]. 2015;39(1):73–7. Available from: http://dx.doi.org/10.1016/j.jcjd.2014.06.005
Sen S, Ramasamy K, Sivaprasad S. Indicators of visual prognosis in diabetic macular oedema. J Pers Med. 2021;11(6).
Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14).
Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022;11(21):1–29.
Zirpel JJ, Pfister IB, Gerhardt C, Garweg JG. Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. Graefe’s Arch Clin Exp Ophthalmol [Internet]. 2021;259(12):3569–78. Available from: https://doi.org/10.1007/s00417-021-05187-z
Massin P, Creuzot-Garcher C, Kodjikian L, Girmens JF, Delcourt C, Fajnkuchen F, et al. Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME). Ophthalmic Res. 2021;64(4):577–86.
Kusuhara S, Shimura M, Kitano S, Sugimoto M, Muramatsu D, Fukushima H, et al. Treatment of diabetic macular edema in real-world clinical practice: The effect of aging. J Diabetes Investig. 2022;13(8):1339–46.
Tatsumi T. Current Treatments for Diabetic Macular Edema. Int J Mol Sci. 2023;24(11).
Al Qassimi N, Kozak I, Al Karam M, Neri P, Aduriz-Lorenzo PM, Attawan A, et al. Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology. Ophthalmol Ther [Internet]. 2022;11(5):1937–50. Available from: https://doi.org/10.1007/s40123-022-00547-2
Man REK, Fenwick EK, Sabanayagam C, Li LJ, Tey CS, Soon HJT, et al. Differential impact of unilateral and bilateral classifications of diabetic retinopathy and diabetic macular edema on vision-related quality of life.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Yovita, Bambang Setiohadji
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
